Latest Corporate Presentation
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer. Checkmate’s product candidate, vidutolimod (CMP-001), is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Checkmate’s goal is to leverage its proprietary technology to discover, develop and commercialize transformative treatments to fight cancer.
- Jan 03, 2022
- Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
- Dec 20, 2021
- Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.
- Jan 10, 2022 7:00 AM EST
- Nov 22, 2021 10:00 AM EST
- Nov 18, 2021 3:00 AM EST